118 related articles for article (PubMed ID: 37861176)
21. Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo.
Ding Q; Zhang W; Cheng C; Mo F; Chen L; Peng G; Cai X; Wang J; Yang S; Liu X
J Cell Physiol; 2020 Mar; 235(3):2911-2924. PubMed ID: 31535374
[TBL] [Abstract][Full Text] [Related]
22. Identification of mitochondrial-related signature and molecular subtype for the prognosis of osteosarcoma.
Zhao X; Zhang J; Liu J; Chen Q; Cai C; Miao X; Wu T; Cheng X
Aging (Albany NY); 2023 Nov; 15(22):12794-12816. PubMed ID: 37976137
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Bruheim S; Xi Y; Ju J; Fodstad O
Clin Cancer Res; 2009 Dec; 15(23):7161-9. PubMed ID: 19920113
[TBL] [Abstract][Full Text] [Related]
24. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
Tsai HC; Huang CY; Su HL; Tang CH
PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
[TBL] [Abstract][Full Text] [Related]
25. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance and immune landscape of a novel ferroptosis-related prognosis signature in osteosarcoma.
Yang L; Liu J; Liu S
BMC Cancer; 2023 Mar; 23(1):229. PubMed ID: 36899330
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
Wu ZY; Shi ZY
Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
29. Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.
Ding M; Ran X; Qian S; Zhang Y; Wang Z; Dong M; Yang Z; Wu S; Feng X; Zhang J; Zhu L; Niu S; Zhang X
Aging (Albany NY); 2023 Dec; 15(24):15360-15381. PubMed ID: 38180104
[TBL] [Abstract][Full Text] [Related]
30. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.
Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ
Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792
[TBL] [Abstract][Full Text] [Related]
31. Construction of a cuproptosis-related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients.
Ni S; Hong J; Li W; Ye M; Li J
Cancer Med; 2023 Feb; 12(4):5009-5024. PubMed ID: 36129020
[TBL] [Abstract][Full Text] [Related]
32. The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma.
Su Z; Wang C; Pan R; Li H; Chen J; Tan J; Tian X; Lin T; Shen J
Front Immunol; 2022; 13():1028263. PubMed ID: 36275679
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells.
Vanas V; Haigl B; Stockhammer V; Sutterlüty-Fall H
PLoS One; 2016; 11(8):e0161023. PubMed ID: 27513462
[TBL] [Abstract][Full Text] [Related]
34. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway.
Liu W; Zhao Z; Wang Y; Li W; Su Q; Jia Q; Zhang J; Zhang X; Shen J; Yin J
Cell Death Dis; 2018 Mar; 9(3):343. PubMed ID: 29497056
[TBL] [Abstract][Full Text] [Related]
35. Verification of Ferroptosis Subcluster-Associated Genes Related to Osteosarcoma and Exploration of Immune Targeted Therapy.
Jiang M; Jike Y; Gan F; Li J; Hu Y; Xie M; Liu K; Qin W; Bo Z
Oxid Med Cell Longev; 2022; 2022():9942014. PubMed ID: 36211822
[TBL] [Abstract][Full Text] [Related]
36. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma.
Jiang J; Chu D; Lai X; Liu L; Tao J
Comput Math Methods Med; 2022; 2022():6314182. PubMed ID: 36388161
[TBL] [Abstract][Full Text] [Related]
37. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue.
Fellenberg J; Krauthoff A; Pollandt K; Delling G; Parsch D
Lab Invest; 2004 Jan; 84(1):113-21. PubMed ID: 14631380
[TBL] [Abstract][Full Text] [Related]
39. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
40. Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients.
Zhang GZ; Wu ZL; Li CY; Ren EH; Yuan WH; Deng YJ; Xie QQ
Front Mol Biosci; 2021; 8():615084. PubMed ID: 34095215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
